What DaVita's Quarter ended Sep 30, 2026 10-Q says: 3 signals
DaVita filed its latest 10-Q with the SEC on Oct 29, 2026. It discusses compliance burden, cybersecurity incident and product launch.
Public (DVA)Hospitals and Health Care10,000+ employeesdavita.comLinkedIn
Get DaVita's live signals in Claude or ChatGPT, or by API
What changed at DaVita this week? Use Autobound signals for davita.com.- Filed
- Oct 29, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 6
Source: Autobound Signal API · 31 signals tracked for DaVita · updated
10-Q · latest 6
What DaVita's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 3 signals
DaVita to Roll Out Expanded Hemodialysis Therapy to Eligible Patients in November
DaVita plans to offer expanded hemodialysis to the vast majority of its eligible patients in November, incurring supplier transition and clinical teammate training costs.
expanded hemodialysishemodiafiltration
CMS issues final ESRD PPS rule projecting 2.7% average reimbursement increase in 2027
On October 28, 2026, CMS issued a final rule updating the Medicare ESRD PPS rate and policies for calendar year 2027, projecting a 2.7% average reimbursement increase for freestanding facilities.
2.7%
projected increase in ESRD freestanding facilities' average reimbursement in 2027
DaVita incurred $25 million in remediation expenses from a 2025 network cybersecurity incident
During the second quarter of 2025, DaVita experienced a cybersecurity incident that disrupted network elements and operations, requiring remediation assistance from third-party cybersecurity professionals.
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 1 signal
DaVita experienced a cybersecurity incident that disrupted network operations, leading to $1.0 million in patient care charges and $12.5 million in general and administrative expenses during remediation with third-party cybersecurity professionals.
- SEC EDGAR
10-Q · Quarter ended Mar 31, 2026
Filed · 2 signals
U.S. Dialysis Patient Care Costs Rose to $280.11 Per Treatment on Higher Wages and Supplies
Patient care costs per treatment increased from $271.77 in Q1 2025 to $280.11 in Q1 2026, driven by higher compensation and wage rates, insurance costs, and medical supplies expense.
3.1%
increase in patient care costs per treatment year-over-year
U.S. Dialysis Operating Income Dropped 9.0% to $506 Million on Higher Patient Care Costs
U.S. dialysis operating income fell 9.0% from $556 million in Q4 2025 to $506 million in Q1 2026, driven by higher compensation and insurance costs per treatment.
$506M
U.S. dialysis operating income in Q1 2026
-9%
decrease in U.S. dialysis operating income compared to Q4 2025
Earnings calls
DaVita earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Expanded Humana partnership adds 10,000 CKD patients upstreamDaVita entered into an expanded partnership with Humana to bring upstream kidney care management to roughly 10,000 chronic kidney disease patients. The partnership directly expands medical spend under management for the outperforming Integrated Kidney Care division. | |
| Nationwide rollout of expanded HD dialyzers starting NovemberDaVita is launching a national rollout of expanded HD dialyzers across its network in November after pilots across 150 centers and 10,000 patients. The new technology is compatible with existing dialysis machines and is targeted to reach approximately 75% of clinically eligible patients, aiming for long-term volume growth by 2029. | |
| Modernizing tech platform with over $1B multi-year investmentDaVita has deployed over $1B in recent years to modernize internal platforms across revenue operations, clinical care management, and labor productivity. While IT spending grew over 20% year-over-year in Q3 creating near-term cost drag, management projects future technology investment growth will decelerate. | |
| CMS ESRD final rule incorporates quarterly TDAPA adjustmentsCMS released the final ESRD rule granting an initial 3.5% rate increase for large dialysis organizations, but add-on TDAPA payments will be recalculated downward quarterly after Q1. The net impact for DaVita is estimated between 1.5% and 2.0% for 2027, where each 1% change equates to $30M in annual revenue. | |
| Patient care cost per treatment rose 2.4% year-over-yearOperating costs per treatment increased 2.4% in Q3 driven by general labor expenses, medical supply costs, and professional liability expenses. These cost increases were only partially offset by lower phosphate binder costs. | |
| ACA exchange shifts driving $40M headwind to commercial mixDaVita is managing an estimated $40M commercial mix headwind in 2026 tied to the expiration of enhanced premium tax credits on ACA exchanges. Commercial revenue declines remain a continuous headwind against overall revenue per treatment. |
Signal API · MCP
Track DaVita with the Signal API
One POST /v1/companies/enrich call with davita.com returns DaVita 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"davita.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about DaVita 10-Q
When did DaVita file its latest 10-Q?
What did DaVita disclose in its latest 10-Q?
What did DaVita say on its recent earnings calls?
Where can I read DaVita's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .